Meyer Halberstam
Internal Medicine · Bronx, NYNPI 1225026511
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,870 of the $142,695 with a category attached, or 95.2%. 35 manufacturers reported payments, led by Lilly USA, LLC at 41.2% of the total. Reporting peaked in 2019 at $37,754 and has fallen 95.8% since, to $1,592 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $406.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$59K
- Boehringer Ingelheim$45K
- AstraZeneca$31K
- Merck$4K
- Sanofi-aventis U.S. LLC$718
- Sanofi$592
- plus $2K from 29 others
What the payments were for
- Consulting fees$4880%
- Speaking & faculty fees$135,87095%
- Travel & lodging$6770%
- Food & beverage$5,6414%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 107 | $58,772 |
| Boehringer Ingelheim | 59 | $45,085 |
| AstraZeneca | 64 | $31,353 |
| Merck | 17 | $3,886 |
| Sanofi-aventis U.S. LLC | 14 | $718 |
| Sanofi | 4 | $592 |
| Amgen | 22 | $431 |
| Sanofi US Services Inc. | 1 | $325 |
| Insulet Corporation | 6 | $224 |
| Dexcom, Inc. | 1 | $160 |
| Xeris Pharmaceuticals, Inc. | 6 | $130 |
| Amneal Pharmaceuticals LLC | 6 | $112 |
| Corcept Therapeutics | 4 | $101 |
| Novo Nordisk | 6 | $97 |
| AbbVie(2 entities) | 3 | $70 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| Mannkind Corporation | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| GRT US Holding, Inc. | 2 | $50 |
| Renalytix AI, Inc. | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $41 |
| Medtronic(2 entities) | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Ionis Pharmaceuticals, Inc. | 1 | $33 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Gilead | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Nevro Corp. | 1 | $24 |
| Radius Health, Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Pfizer | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$102,658
- FARXIGA$30,657
- STEGLATRO$3,640
- SOLIQUA 100/33$970
- TOUJEO$185
- DEXCOM G7 GSS (161)$160
- DEXCOM STELO GLUCOSE BIOSENSOR$160
- Omnipod$105
How this compares
$142,695 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 310 | $326,914 |
| TrulicityDulaglutide | 294 | $303,147 |
| JardianceEmpagliflozin | 440 | $269,945 |
| OzempicSemaglutide | 178 | $173,253 |
| FarxigaDapagliflozin Propanediol | 153 | $93,869 |
| JanuviaSitagliptin Phosphate | 127 | $81,294 |
| TradjentaLinagliptin | 125 | $74,835 |
| ProliaDenosumab | 36 | $60,599 |
| JanumetSitagliptin Phos/Metformin Hcl | 92 | $45,612 |
| DapagliflozinDapagliflozin Propanediol | 40 | $24,712 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 64 | $21,043 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 24 | $18,794 |
| RybelsusSemaglutide | 21 | $17,961 |
| SteglatroErtugliflozin Pidolate | 38 | $11,601 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $11,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $58,772 | $630,061604 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy | $45,085 | $359,777587 claims |
| Novo NordiskOzempic, Rybelsus | $97 | $191,214199 claims |
| MerckJanuvia, Janumet, Janumet Xr, Steglatro | $3,886 | $157,300281 claims |
| AstraZenecaFarxiga, Lokelma | $31,353 | $105,015168 claims |
| AmgenProlia | $431 | $60,59936 claims |
| Johnson & JohnsonInvokana | $12 | $10,97420 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $112 | $4,968558 claims |
| AbbVieSynthroid | $70 | $1,45328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Jason LeiderBronx$694K
- Bulent AtacBronx$647K
- Timothy KanterBronx$630K
- Shervin MortazaviBronx$374K
- Elizabeth Jenny-AvitalBronx$185K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.